Nanoformulated Antiretroviral Therapy Attenuates Brain Metabolic Oxidative Stress.

ABSTRACT: Antiretroviral therapy (ART) restricts human immunodeficiency virus type one (HIV-1) replication and by so doing, improves the quality and longevity of life for infected people. Nonetheless, treatment can also lead to adverse clinical outcomes such as drug resistance and systemic adverse events. Both could be affected by long-acting slow effective release ART. Indeed, maintenance of sustained plasma drug levels, for weeks or months, after a single high-level dosing, could improve regimen adherence but, at the same time, affect systemic toxicities. Of these, the most troubling are those that affect the central nervous system (CNS). To address this, dolutegravir (Tivicay, DTG), a potent and durable HIV integrase inhibitor used effectively in combination ART was tested. Rodents were administe

SUBMITTER: Montenegro-Burke JR 

PROVIDER: S-EPMC6403019 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature